article thumbnail

Trends in direct health care costs among US adults with atherosclerotic cardiovascular disease with and without diabetes

Cardiovascular Diabetology

Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce. Individuals with diabetes had a 1.5-fold fold higher mean expenditure that those without diabetes. individuals aged ≥ 18 years.

article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

article thumbnail

Hypoglycemic Events May Trigger Acute Ischemic Stroke Within 30 Days in Those With Diabetes: A Case-Crossover Study

Stroke Journal

We used conditional logistical regression models to estimate odds ratios and 95% CIs.RESULTS:There were 237 667 index admissions with AIS and diabetes during the study period. These results, if confirmed in other studies, emphasize the importance of avoiding hypoglycemic events in patients with diabetes.

article thumbnail

Abstract WP278: Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes

Stroke Journal

Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

article thumbnail

Impact of Residential Social Deprivation on Prediction of Heart Failure in Patients With Type 2 Diabetes: External Validation and Recalibration of the WATCH-DM Score Using Real World Data

Circulation: Cardiovascular Quality & Outcomes

Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. As social determinants of health are rarely included in risk models, we validated and recalibrated the WATCH-DM score in a diverse patient-group using their social deprivation index (SDI).Methods:We

article thumbnail

Abstract WP229: Comparing the Real-World Effects of Once-Weekly Semaglutide and Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcomes, Health Care Resource Utilization, and Medical Costs in Individuals With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Stroke Journal

When compared with placebo, glucagon-like peptide-1 receptor agonists such as once-weekly semaglutide (semaglutide OW T2D) improve cardiovascular outcomes in people with type 2 diabetes (T2D), whereas dipeptidyl peptidase-4 inhibitors (DPP-4is) do not. However, no head-to-head trials of these 2 incretin-based drug classes have been conducted.